Jaguar Health (JAGX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
6 May, 2026Executive summary
Supplement corrects the Annual Meeting date to Friday, May 22, 2026, amending a previous error that listed it as Tuesday, August 19, 2025.
All other information in the Proxy Statement remains unchanged and should be read in conjunction with this supplement.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Jaguar Health
- Transformative year with major funding, rare disease focus, and breakthrough clinical results.JAGX
Emerging Growth Conference 9310 Jun 2026 - Supplement amends share issuance terms to C/M Capital, clarifying caps, pricing, and use of proceeds.JAGXProxy filing29 May 2026
- Crofelemer advances in rare disease trials, targeting NDA filing for MVID in mid-2027.JAGXLytham Partners Spring 2026 Investor Conference29 May 2026
- Q1 2026 net revenue jumped 816% year-over-year, fueled by a major licensing deal and strategic shift.JAGXQ1 202627 May 2026
- Major licensing deal fuels rare disease pipeline and record revenue growth in early 2026.JAGXCorporate presentation26 May 2026
- Major stock issuances to C/M Capital and board governance changes are up for shareholder vote.JAGXProxy filing30 Apr 2026
- Shareholders will vote on major stock issuances to C/M Capital, director election, and auditor ratification.JAGXProxy filing21 Apr 2026
- Q4 2025 revenue up 5% sequentially; $16M upfront from out-license deal, net loss at $53.6M.JAGXQ4 202510 Apr 2026
- Proxy seeks approval for major share increase, reverse splits, and note-related share issuance.JAGXProxy filing24 Mar 2026